8:51 AM ET
Earnings Call
▶ Call
Intensity Therapeutics Earnings Call: Key Takeaways
Intensity Therapeutics is restarting Phase 3 and Phase 2 trials after funding-related pauses, but remains severely capital-constrained with only $8.5 million in cash, making future enrollment timelines entirely dependent on successful capital raises.
- Call
- Nov 5, 2026, 8:00 AM ET